Back to discover
Drug

Acetylgalactosamine

Research stage
Emerging researchRising momentum
RxNorm202ChEMBLCHEMBL39064UNIIKM15WK8O5T
3
Research papers
Latest activity
beta

Recent clinical, regulatory, research and industry developments relating to this drug.

O-GalNAc glycans are enriched in neuronal tracts and regulate nodes of Ranvier.

Research2025-02-25Proceedings of the National Academy of Sciences of the United States of America

Therapeutic siRNA: State-of-the-Art and Future Perspectives.

Research2022-08-23BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy

Therapeutic siRNA: state of the art.

Research2020-06-19Signal transduction and targeted therapy

Profile

Identifiers & mechanism

Canonical identifiers, marketed brand names and mechanism, resolved across RxNorm, ChEMBL and ATC.

Canonical name
Acetylgalactosamine
RxNorm CUI
202
ChEMBL ID
CHEMBL39064
UNII
KM15WK8O5T

Research activity

3 papers

Key research shaping understanding of this drug, combining the latest publications with the most influential evidence.

Publications over time
20202025
Most influential

Therapeutic siRNA: state of the art.

Signal transduction and targeted therapy · 2020 · 991 cites

Therapeutic siRNA: State-of-the-Art and Future Perspectives.

BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy · 2022 · 256 cites

O-GalNAc glycans are enriched in neuronal tracts and regulate nodes of Ranvier.

Proceedings of the National Academy of Sciences of the United States of America · 2025 · 7 cites
Recent papers

O-GalNAc glycans are enriched in neuronal tracts and regulate nodes of Ranvier.

Proceedings of the National Academy of Sciences of the United States of America · 2025 · 7 cites

Therapeutic siRNA: State-of-the-Art and Future Perspectives.

BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy · 2022 · 256 cites

Therapeutic siRNA: state of the art.

Signal transduction and targeted therapy · 2020 · 991 cites
Major research themes5
Acetylgalactosamine2Neurons1Polysaccharides1Prealbumin1Ranvier's Nodes1
Journals, researchers & institutions
Top journals
  • BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy1
  • Proceedings of the National Academy of Sciences of the United States of America1
  • Signal transduction and targeted therapy1
Leading researchers
  • Aigner A1
  • Cummings RD1
  • Friedrich M1
  • Hu B1
  • Huang Y1
  • Liang XJ1
  • Mealer RG1
  • Noel M1
Leading institutions
free-text, unnormalised
  • Aix-Marseille University1
  • Beth Israel Deaconess Medical Center1
  • Chinese Academy of Sciences (CAS)1
  • Fraunhofer Institute for Cell Therapy and Immunology IZI1
  • Institute of Clinical Immunology1
  • National Center for International Biotargeting Theranostics1

Related drugs

2 matches

Drugs sharing diseases, protein targets and literature with this one. Ranked by graph evidence (shared targets + diseases weighted above co-mentions).

Givosiran

Studied across the same disease area as Acetylgalactosamine in the shared literature.

1 shared disease1 shared paper
Patisiran

Studied across the same disease area as Acetylgalactosamine in the shared literature.

1 shared disease1 shared paper
References & data sources
  • RxNorm (U.S. National Library of Medicine) — drug identity
  • ChEMBL (EMBL-EBI) & UniProt — pharmacology and targets
  • Europe PMC — research literature